Ofri Mosenzon, MD: DECLARE-TIMI 58 Results

(6:26)

DECLARE-TIMI 58 HFrEF | ACC.19

(4:22)

DECLARE: The Dapagliflozin Effect on Cardiovascular Events - Medpage Today

(3:5)

Clinical Drug Trial Designs: Are Clinical Trials Becoming More Patient Friendly? - by Patient Power

(7:13)

Rob Mentz, MD: The CANVAS Study and SGLT-2 Inhibitors

(1:40)

ACC Decision Pathway on CV Risk Reduction in T2D and ASCVD

(35:39)

CREPI - Prevalencia e incidencia de complicaciones microvasculares y macrovasculares durante 15 años

(1:59:4)

비만치료제 위고비, 중단하면 요요현상 올까? - 68주 아닌 단기간의 효과는 얼마나 될까?

(5:2)

Richard Swinburne: The Existence of God

(48:23)

【醫生會客室】周振中（一）糖尿病患者做好風險管理可保生活質素

(6:9)

EHJ Today - The EMPA-REG OUTCOME Trial

(11:19)

Dr.Atul Kalhan(UK): Dapagliflozin in type 2 diabetes; the global story of success

(30:16)

How to interpret clinical trial data – Examples from recent clinical trials

(37:30)

INSULINA DE ACCION ULTRALARGA Es icodec el avance que estábamos esperando

(12:)

Diabetes: A New Breakthrough

(58:22)

Dr.Hemant Thacker(Mumbai):Canagliflozin: Where can we place in the therapy?

(28:34)

Results DECLARE-TIMI 58

(5:10)

EASD 2019 : DECLARE-TIMI 58 - Prof Itamar Raz

(6:30)

Poised on a Paradigm Shift | The REWIND and DECLARE Trials

(9:5)

Stephen Wiviott, MD: Strengths and Limitations of the DECLARE-TIMI 58 Trial

(2:10)

Reducing the progression of kidney disease in type 2 diabetes patients

(7:14)

Examining Cardiovascular Outcomes Trials

(7:27)

Stephen D Wiviott, MD,: The Dapagliflozin Effect on Cardiovascular Events (DECLARE-TIMI 58) Trial

(4:53)

Cardiovascular Risks Reduction in Diabesity-Latest Evidence from DECLARE-TIMI 58(4)

(5:46)

AHA 2018: DECLARE TIMI-58- Prof Stephen D. Wiviott

(7:5)

SGLT-2 in cardiovascular and kidney outcomes DECLARE TIMI 58

(3:32)

Stephen Wiviott, MD: DECLARE-TIMI 58 Trial

(3:9)

Controlling Diabetes With SGLT-2 Inhibitors May Also Reduce Heart Failure or Kidney Disease

(1:35)

Dissecting the CANVAS trial | Carol Wysham and Lori Berard

(11:15)

SYNTAX II Trial: 5yr Data Shows Reduction in MACE in PCI | Prof Adrian Banning

(2:8)